X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare IPCA Labs with AANJANEYA LIFECARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs DR. DATSONS LABS - Comparison Results

IPCA LABS    Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS DR. DATSONS LABS IPCA LABS/
DR. DATSONS LABS
 
P/E (TTM) x 35.0 -10.9 - View Chart
P/BV x 3.3 0.2 2,048.5% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 IPCA LABS   DR. DATSONS LABS
EQUITY SHARE DATA
    IPCA LABS
Mar-17
DR. DATSONS LABS
Mar-14
IPCA LABS/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs643126 511.9%   
Low Rs50331 1,627.2%   
Sales per share (Unadj.) Rs254.4133.0 191.3%  
Earnings per share (Unadj.) Rs16.10.2 10,599.3%  
Cash flow per share (Unadj.) Rs29.86.6 450.6%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs194.6128.8 151.1%  
Shares outstanding (eoy) m126.2031.66 398.6%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x2.30.6 382.7%   
Avg P/E ratio x35.7516.1 6.9%  
P/CF ratio (eoy) x19.211.8 162.5%  
Price / Book Value ratio x2.90.6 484.7%  
Dividend payout %6.20-   
Avg Mkt Cap Rs m72,3002,477 2,918.4%   
No. of employees `00013.3NA-   
Total wages/salary Rs m6,96056 12,428.2%   
Avg. sales/employee Rs Th2,413.5NM-  
Avg. wages/employee Rs Th523.2NM-  
Avg. net profit/employee Rs Th152.4NM-  
INCOME DATA
Net Sales Rs m32,1064,211 762.5%  
Other income Rs m22679 286.8%   
Total revenues Rs m32,3324,289 753.8%   
Gross profit Rs m4,448569 782.2%  
Depreciation Rs m1,730204 846.1%   
Interest Rs m241430 56.0%   
Profit before tax Rs m2,70313 21,285.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6756 11,068.9%   
Profit after tax Rs m2,0285 42,250.0%  
Gross profit margin %13.913.5 102.6%  
Effective tax rate %25.048.0 52.0%   
Net profit margin %6.30.1 5,540.8%  
BALANCE SHEET DATA
Current assets Rs m17,3406,852 253.1%   
Current liabilities Rs m9,5596,711 142.5%   
Net working cap to sales %24.23.3 723.7%  
Current ratio x1.81.0 177.7%  
Inventory Days Days100161 62.4%  
Debtors Days Days57318 17.9%  
Net fixed assets Rs m20,7793,673 565.7%   
Share capital Rs m252317 79.7%   
"Free" reserves Rs m24,4993,761 651.4%   
Net worth Rs m24,5534,078 602.1%   
Long term debt Rs m3,5171,671 210.5%   
Total assets Rs m39,59512,633 313.4%  
Interest coverage x12.21.0 1,187.5%   
Debt to equity ratio x0.10.4 35.0%  
Sales to assets ratio x0.80.3 243.3%   
Return on assets %5.73.4 166.4%  
Return on equity %8.30.1 7,016.5%  
Return on capital %10.57.7 136.7%  
Exports to sales %48.622.9 212.5%   
Imports to sales %14.214.3 99.6%   
Exports (fob) Rs m15,617964 1,620.1%   
Imports (cif) Rs m4,571602 759.4%   
Fx inflow Rs m15,617964 1,620.1%   
Fx outflow Rs m5,828607 959.9%   
Net fx Rs m9,790357 2,743.0%   
CASH FLOW
From Operations Rs m2,7641,345 205.5%  
From Investments Rs m-1,432-2,256 63.5%  
From Financial Activity Rs m-1,591-1,200 132.6%  
Net Cashflow Rs m-259-2,111 12.3%  

Share Holding

Indian Promoters % 45.9 4.5 1,013.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.4 0.0 -  
FIIs % 25.3 1.4 1,874.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 94.1 18.5%  
Shareholders   36,892 20,807 177.3%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NOVARTIS  ASTRAZENECA PHARMA  DISHMAN PHARMA  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare IPCA LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Energy Stocks Lose(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.4% while the Hang Seng is down 0.5%. The Shanghai Composite is trading up by 0.2%.

Related Views on News

IPCA LABS Announces Quarterly Results (4QFY18); Net Profit Up 15.6%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, IPCA LABS has posted a net profit of Rs 513 m (up 15.6% YoY). Sales on the other hand came in at Rs 8 bn (up 17.6% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Jun 25, 2018 11:19 AM

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

IPCA LABS - BIOCON LTD COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS